Pre-clinical Research: is a level of research that begins before clinical trials can begin, and during which important feasibility, constant testing and drug safety data are collected. The aim of a preclinical study is to collect data in support of the safety of the new treatment. Preclinical studies are required before clinical trials in humans can be started.
Appropriate dosing of pharmaceuticals is critical to prevent sub-therapeutic efficacy or the occurrence of adverse events. However, genetic variability may significantly influence an individu...
Introduction and adoption of whole-genome sequencing has enabled new methods of investigation in the quest for answers in diagnostic odyssey cases as well as in the broader study of genetic d...
Cancer immunotherapy has demonstrated promising results. However, to date, researchers have failed to overcome the complex interplay between the immune system and the immune suppressive tumor...
As one of the nation's most prevalent sexually transmitted infections, genital herpes represents a diagnostic and therapeutic challenge to clinicians, laboratorians and the patients they...
As hospitals and healthcare systems move toward value-based care, new management systems are needed to measure and improve clinical processes. This presents both an opportunity and a ch...
Medical Technology Partner’s presentation is designed highlight what Medicare is proposing to do based on the Protecting Access to Medicare Act of April 1, 2014 with regard to clinical...
This lecture will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry and molecular diagnostics. The lecture will provide a general...
Diagnosis and management of CKD requires a spectrum of diagnostic tests to not only diagnose kidney function but also determine the status of other complications due to CKD, including creatin...
In November of 2013 the AHA/ACA jointly proposed new guidelines for the management of hypercholesterolemia, the first full update in over a decade. The charge was to create evidence bas...
DNASTAR offers an integrated suite of software for accurate assembly, alignment, and analysis of sequence data from all major next-generation sequencing platforms, supporting key workflows in...
Until recently most of the phenotypic information on congenital endocrine disorders have relied on biochemical testing of steroids, biogenic amines and peptides but is now...
Aggressive low-density lipoprotein cholesterol (LDL-C) lowering strategies are recommended for prevention of cardiovascular events in high-risk populations. Guidelines recommend a 30-50% redu...
Liquid chromatography triple quadrupole mass spectrometry (LC/MS/MS) is ideally suited for the direct and rapid analysis of prepared biological samples. While analysis times can be shortened...
FDA has generally not enforced applicable regulatory requirements on a group of IVD tests called Laboratory Developed Tests. This use of “enforcement discretion” has been un...
There is agreement among clinicians that laboratory analyses are indispensable for correct diagnosis of disease, therapy, and patient monitoring. It is evident that laboratory data should be...
Drugs of abuse toxicology testing by immunoassays is widely used clinically, but also known to be inadequate for many clinical indications. In this presentation, the speaker will outline diff...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterog...
Date: Nov 10, 2015 8AM Pacific, 11AM Eastern, 4PM GMT
Transporting smaller volumes of a sample, injecting less matrix, examining lower limits of detection and staying ahead of government r...
Detection of rare mutations is required for reliable identification of mutations in liquid biopsies and heterogeneous tumors. Yet low-level mutation detection remains a technically challengin...
The 95% failure rate of anticancer therapeutic being approved after positive Phase III trials suggests that existing pre-clinical approaches and tools are inadequate predictors of clinical ou...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Recent evidence demonstrating the importance of structural complexity in advancing compounds to the clinic points to the need for enhancing small molecule screening collections with sp3-rich ...
DATE: July 22, 2015TIME: 9:00AM PT, 12:00PM ETHuman induced pluripotent stem cells (iPSCs) bring human biology into pre-clinical aspects of drug discovery. iPSC-derived cardiomyocytes have em...
Appropriate dosing of pharmaceuticals is critical to prevent sub-therapeutic efficacy or the occurrence of adverse events. However, genetic variability may significantly influence an individu...
Introduction and adoption of whole-genome sequencing has enabled new methods of investigation in the quest for answers in diagnostic odyssey cases as well as in the broader study of genetic d...
Cancer immunotherapy has demonstrated promising results. However, to date, researchers have failed to overcome the complex interplay between the immune system and the immune suppressive tumor...
As one of the nation's most prevalent sexually transmitted infections, genital herpes represents a diagnostic and therapeutic challenge to clinicians, laboratorians and the patients they...
As hospitals and healthcare systems move toward value-based care, new management systems are needed to measure and improve clinical processes. This presents both an opportunity and a ch...
Medical Technology Partner’s presentation is designed highlight what Medicare is proposing to do based on the Protecting Access to Medicare Act of April 1, 2014 with regard to clinical...
This lecture will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry and molecular diagnostics. The lecture will provide a general...
Diagnosis and management of CKD requires a spectrum of diagnostic tests to not only diagnose kidney function but also determine the status of other complications due to CKD, including creatin...
In November of 2013 the AHA/ACA jointly proposed new guidelines for the management of hypercholesterolemia, the first full update in over a decade. The charge was to create evidence bas...
DNASTAR offers an integrated suite of software for accurate assembly, alignment, and analysis of sequence data from all major next-generation sequencing platforms, supporting key workflows in...
Until recently most of the phenotypic information on congenital endocrine disorders have relied on biochemical testing of steroids, biogenic amines and peptides but is now...
Aggressive low-density lipoprotein cholesterol (LDL-C) lowering strategies are recommended for prevention of cardiovascular events in high-risk populations. Guidelines recommend a 30-50% redu...
Liquid chromatography triple quadrupole mass spectrometry (LC/MS/MS) is ideally suited for the direct and rapid analysis of prepared biological samples. While analysis times can be shortened...
FDA has generally not enforced applicable regulatory requirements on a group of IVD tests called Laboratory Developed Tests. This use of “enforcement discretion” has been un...
There is agreement among clinicians that laboratory analyses are indispensable for correct diagnosis of disease, therapy, and patient monitoring. It is evident that laboratory data should be...
Drugs of abuse toxicology testing by immunoassays is widely used clinically, but also known to be inadequate for many clinical indications. In this presentation, the speaker will outline diff...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
Next-generation sequencing has emerged as a valuable tool for generating patient-specific genetic information for clinical diagnostics and optimal selection of targeted therapies. The heterog...
Date: Nov 10, 2015 8AM Pacific, 11AM Eastern, 4PM GMT
Transporting smaller volumes of a sample, injecting less matrix, examining lower limits of detection and staying ahead of government r...
Detection of rare mutations is required for reliable identification of mutations in liquid biopsies and heterogeneous tumors. Yet low-level mutation detection remains a technically challengin...
The 95% failure rate of anticancer therapeutic being approved after positive Phase III trials suggests that existing pre-clinical approaches and tools are inadequate predictors of clinical ou...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Recent evidence demonstrating the importance of structural complexity in advancing compounds to the clinic points to the need for enhancing small molecule screening collections with sp3-rich ...
DATE: July 22, 2015TIME: 9:00AM PT, 12:00PM ETHuman induced pluripotent stem cells (iPSCs) bring human biology into pre-clinical aspects of drug discovery. iPSC-derived cardiomyocytes have em...
Follow
